| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
86,568,000 |
| Market
Cap: |
1.33(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.79 - $20.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Scholar Rock is a biopharmaceutical company focused on the discovery and development of medicines for the treatment of serious diseases. Co. has progressed the development of: Apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy; SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies; selective inhibitors of the activation of transforming growth factor beta for the treatment of fibrotic diseases; and additional discovery and early preclinical programs related to the selective modulation of growth factor signaling.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
6,579,493 |
8,088,052 |
| Total Buy Value |
$0 |
$0 |
$45,086,736 |
$53,421,765 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
3 |
9 |
| Total Shares Sold |
26,110 |
103,816 |
107,114 |
108,208 |
| Total Sell Value |
$411,056 |
$1,780,570 |
$1,802,142 |
$1,812,515 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
5 |
12 |
14 |
15 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gilman Michael |
Director |
– • – |
2021-02-08 |
4 |
AS |
$65.06 |
$117,361 |
D/D |
(1,804) |
42,155 |
|
-49% |
|
| Myles Edward H |
Chief Financial Officer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
24,150 |
24,150 |
|
- |
|
| Carven Gregory John |
Head of Research |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,600 |
12,600 |
|
- |
|
| Kingsley Stuart A |
President and CEO |
• • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
42,000 |
42,000 |
|
- |
|
| Chyung Yung H. |
Chief Medical Officer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,750 |
15,750 |
|
- |
|
| Carven Gregory John |
Head of Research |
• – – |
2021-01-27 |
4/A |
AS |
$55.87 |
$1,080,402 |
D/D |
(19,100) |
32,734 |
|
- |
|
| Carven Gregory John |
Head of Research |
• – – |
2021-01-27 |
4 |
AS |
$55.87 |
$1,080,402 |
D/D |
(19,100) |
26,860 |
|
-51% |
|
| Carven Gregory John |
Head of Research |
• – – |
2021-01-27 |
4 |
OE |
$15.11 |
$100,013 |
D/D |
6,619 |
82,734 |
|
- |
|
| Gilman Michael |
Director |
– • – |
2021-01-26 |
4 |
AS |
$57.99 |
$207,469 |
D/D |
(3,501) |
43,959 |
|
-52% |
|
| Gilman Michael |
Director |
– • – |
2021-01-26 |
4 |
OE |
$5.77 |
$20,201 |
D/D |
3,501 |
47,460 |
|
- |
|
| Carven Gregory John |
Head of Research |
• – – |
2021-01-26 |
4/A |
AS |
$60.65 |
$219,687 |
D/D |
(3,607) |
51,834 |
|
- |
|
| Carven Gregory John |
Head of Research |
• – – |
2021-01-26 |
4 |
AS |
$57.91 |
$2,184,820 |
D/D |
(36,774) |
45,960 |
|
-52% |
|
| Carven Gregory John |
Head of Research |
• – – |
2021-01-26 |
4 |
OE |
$5.77 |
$273,822 |
D/D |
30,900 |
76,115 |
|
- |
|
| Carven Gregory John |
Head of ResearchOfficer |
• – – |
2020-06-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
45,215 |
|
70% |
|
39 Records found
|
|
Page 2 of 2 |
|
|
0.25 (1.66%) 
